Terkko Navigator / Porkka, K(immo)*

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia

Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML

Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies

<em>ERCC6L2</em> defines a novel entity within inherited acute myeloid leukemia

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL

Dasatinib and navitoclax act synergistically to target NUP98-NSD1⁺/FLT3-ITD⁺ acute myeloid leukemia

Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

Germline alterations in a consecutive series of acute myeloid leukemia

Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia

Applications of genomic medicine in the treatment of diseases

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia

IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling

Enrichment of rare variants in population isolates: single AICDA mutation responsible for hyper-IgM syndrome type 2 in Finland

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity